0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover370.26%IV-69.84%PremiumOct 18, 2024Expiry Date5.79Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9638Delta0.0108Gamma1.39Leverage Ratio-0.0141Theta0.0012Rho1.34Eff Leverage0.0016Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet